Share on StockTwits

Sarepta Therapeutic (NASDAQ:SRPT) has earned a consensus rating of “Hold” from the eighteen ratings firms that are covering the stock, Stock Ratings Network.com reports. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and eight have assigned a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $38.72.

A number of analysts have recently weighed in on SRPT shares. Analysts at Deutsche Bank raised their price target on shares of Sarepta Therapeutic from $17.00 to $35.00 in a research note on Tuesday. They now have a “hold” rating on the stock. Separately, analysts at Citigroup Inc. upgraded shares of Sarepta Therapeutic from a “sell” rating to a “neutral” rating in a research note on Tuesday. Finally, analysts at Canaccord Genuity upgraded shares of Sarepta Therapeutic from a “hold” rating to a “buy” rating in a research note on Monday. They now have a $63.00 price target on the stock, up previously from $27.00.

Shares of Sarepta Therapeutic (NASDAQ:SRPT) opened at 38.19 on Friday. Sarepta Therapeutic has a one year low of $12.12 and a one year high of $55.61. The stock’s 50-day moving average is $26.78 and its 200-day moving average is $26.95. The company’s market cap is $1.443 billion.

Sarepta Therapeutic (NASDAQ:SRPT) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by $0.08. The company had revenue of $2.60 million for the quarter, compared to the consensus estimate of $4.53 million. During the same quarter in the previous year, the company posted ($2.36) earnings per share. The company’s revenue for the quarter was down 64.4% on a year-over-year basis. Analysts expect that Sarepta Therapeutic will post $-3.39 EPS for the current fiscal year.

Sarepta Therapeutics Inc, formerly AVI BioPharma, Inc, is a biopharmaceutical company focused on the discovery and development of ribonucleic acid (NASDAQ:SRPT)-based therapeutics for the treatment of both rare and infectious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.